GlassScriptPhysician profile
Eduardo Miguel Martinez
NPI 1891957940
$7,421.58
in general payments reported to CMS, 2019-2025
29 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $2,013 · 2021: $1,541 · 2022: $548 · 2023: $2,117 · 2024: $308 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,500 · Food and Beverage: $857 · Travel and Lodging: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,500.00 |
| Food and Beverage | $856.81 |
| Travel and Lodging | $231.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,429.28 | 2019-2020 | |
| Intuitive Surgical, INC. | $2,100.05 | 2022-2023 | Davinci Xi, Da Vinci Surgical System |
| Axonics, INC. | $1,468.56 | 2021-2024 | Axonics |
| Abbvie INC. | $308.10 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $195.40 | 2023-2025 | Gemtesa |
| Femselect INC. | $106.26 | 2024 | Enplace |
| Mayne Pharma Commercial LLC | $92.37 | 2021-2023 | |
| Pfizer INC. | $81.05 | 2021-2023 | |
| Hologic Sales and Service, LLC | $71.39 | 2021-2025 | Thinprep 2000 Processor, Aptima |
| Organon LLC | $61.59 | 2023-2024 | Nexplanon |
| Astellas Pharma US INC | $53.56 | 2019-2020 | |
| Urovant Sciences INC | $52.93 | 2021-2022 | |
| Mission Pharmacal Company | $45.92 | 2021-2023 | Uribel |
| Exeltis, USA INC. | $45.30 | 2023-2024 | Slynd |
| Daiichi Sankyo INC. | $41.98 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedrion Biopharma, INC. | $24.73 | 2024 | Kedrab, Albuked, Rhogam Ultra-Filtered Plus |
| Amgen INC. | $24.67 | 2019 | |
| Cepheid | $24.48 | 2025 | Genexpert |
| Bayer Healthcare Pharmaceuticals INC. | $22.41 | 2020 | |
| Myovant Sciences INC. | $22.18 | 2021 | |
| Therapeuticsmd, INC. | $20.28 | 2021 | |
| Duchesnay USA Incorporated | $19.16 | 2019 | |
| Heron Therapeutics, INC. | $16.92 | 2022 | |
| Provepharm INC. | $16.39 | 2025 | Bludigo |
| Organogenesis INC. | $16.33 | 2022 | |
| Coopersurgical, INC. | $16.09 | 2025 | Paragard T 380a |
| Coloplast Corp | $15.57 | 2021 | |
| Allergan, INC. | $15.28 | 2019 | |
| Avion Pharmaceuticals | $13.35 | 2023 | Balcoltra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.